IgM Monoclonal Gammopathies Demand a Neurologic and Hematologic Workup
Peripheral neuropathies linked to immunoglobulin M monoclonal gammopathies and low-grade B-cell lymphomas sit at the intersection of two specialties because the neurologic syndrome is not a single disease. Some patients develop immune-mediated neuropathy, most often through antibodies directed against myelin-associated glycoprotein MAG; others develop nerve injury through direct infiltration, as in neurolymphomatosis or Bing-Neel syndrome, or through protein deposition, including AL amyloidosis. The clinical challenge begins with attribution. A monoclonal protein in the blood does not automatically explain the neuropathy, and a neuropathy in a patient with an IgM clone does not always justify treatment of the clone.
That distinction drives the entire diagnostic pathway. Establishing causality is the first therapeutic decision, because only neuropathies truly linked to the gammopathy should lead to clone-directed intervention.
Anti-MAG Neuropathy Remains the Prototype
Among the IgM-related syndromes, anti-MAG neuropathy remains the most common and best-characterized entity. Its biology is rooted in an immune attack on peripheral myelin, which helps explain the typical chronic course and the need for careful clinical correlation rather than reflex treatment based solely on a laboratory abnormality. The review frames this disorder as the reference point for the broader category because it is where diagnosis, mechanism, and treatment strategy most clearly align.
The broader differential remains essential. Immune-mediated neuropathy, infiltrative disease, and deposition disease can all present with progressive neurologic symptoms, yet the mechanism determines the workup and the management. A patient with neurolymphomatosis requires a different approach from one with an antibody-mediated demyelinating process. Likewise, AL amyloidosis brings a separate set of organ-risk considerations and should not be conflated with anti-MAG disease simply because an IgM monoclonal protein is present.
The practical consequence is straightforward: neurologists and hematologists need to evaluate the patient together, not sequentially.
Why Clone-Directed Therapy Now Matters More
Over the past decade, treatment has shifted away from a purely symptomatic mindset toward clone-directed approaches. The review identifies two major therapeutic directions: anti-CD20-based regimens and covalent Bruton tyrosine kinase inhibitors (cBTKi). Both strategies aim to suppress the pathogenic B-cell clone responsible for the paraprotein and, in immune-mediated cases, the downstream antibody production that injures peripheral nerves.
This biologic rationale is compelling. If the monoclonal clone is generating the offending antibody, then reducing the clone should reduce ongoing nerve damage. If the disease is infiltrative, direct suppression of the malignant clone addresses the source of neural invasion. Even in that mechanistic clarity, clinical evidence remains limited. High-quality comparative data are still scarce, and the review makes clear that treatment decisions often rest on biologic plausibility, disease trajectory, and functional impact rather than on a large randomized evidence base.
Treatment Is Best Reserved for Progressive, Functionally Impairing Disease
Not every patient with an IgM gammopathy and neuropathy requires immediate therapy. Management should be individualized and reserved primarily for progressive disease that is impairing function. That threshold matters because many of these neuropathies evolve slowly, and some patients may remain stable enough that the risks of systemic therapy outweigh the benefits.
The review’s clinical stance is cautious but not passive. Once the neuropathy is clearly linked to the clone and is worsening enough to affect daily life, treatment becomes more compelling. In that setting, the goal is not only to suppress laboratory markers but to slow or halt neurologic decline. Sensory loss, gait instability, and weakness can leave lasting disability even when hematologic control is achieved, which is why timing the intervention to disease activity rather than to anxiety about the paraprotein is so important.
Progression and disability, not the monoclonal protein alone, should drive treatment.
Persistent Disability Keeps the Field From Settling
Even with newer clone-directed strategies, many patients continue to experience residual neurologic impairment. Peripheral nerves recover slowly, and some damage may be irreversible by the time treatment begins. That reality explains why the review emphasizes the need for novel strategies and prospective clinical trials built around validated neurologic endpoints. Hematologic response alone is not enough in this setting; the field needs measures that capture what matters to patients, including strength, sensation, gait, and function.
The gap between biologic control and clinical recovery is especially important in anti-MAG neuropathy, where symptoms can remain despite suppression of the clone. It also complicates the use of response metrics borrowed from hematology, which may not fully reflect nerve recovery. A treatment can be active against the B-cell clone and still leave the patient with a fixed disability burden if axonal injury has already accumulated.
A Multidisciplinary Model Is No Longer Optional
The review ends where many real-world cases begin: with uncertainty about whether the gammopathy is causal and, if so, which mechanism is responsible. Neurologists bring the phenotype, hematologists bring the clone assessment, and together they determine whether the patient has an immune-mediated anti-MAG syndrome, infiltrative disease, or a deposition process such as amyloidosis. That collaborative model is not just organizational convenience. It is the only way to avoid overtreating incidental monoclonal gammopathy while also avoiding delay in patients whose neuropathy is genuinely clone-driven.
The therapeutic horizon is broader than it was a decade ago, but it is not yet mature. Anti-CD20-based regimens and cBTKi have expanded options, yet the absence of robust prospective trials leaves major questions unanswered about comparative effectiveness, durability, and neurologic recovery. For now, the most defensible approach is careful phenotyping, confirmation of causality, and selective treatment of patients with progressive, functionally limiting disease. The remaining problem is not whether the clone can be targeted, but how best to measure whether the nerve is truly better.